20 articles
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
Phase 1 trial examines whether vesatolimod can safely stimulate immune response in HIV controllers during treatment interruption.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
New research reveals metformin can silence HIV and boost immune control, offering hope for treatment-free remission.
New research reveals why giving multiple doses of a promising type 1 diabetes treatment doesn't improve outcomes beyond a single course.
New research reveals how a single antibody treatment creates lasting protection against autoimmune diabetes by reshaping immune cells.
JAMA publishes a timely review of IgA nephropathy, the leading cause of primary glomerulonephritis worldwide, amid a wave of new therapies.
Natural flavonoid fisetin activates mitophagy and xenophagy pathways to restrict intracellular Salmonella growth in immune cells.
Phase I trial tests selective JAK3 inhibitor with improved safety profile compared to existing treatments for inflammatory conditions.
Combination therapy with guselkumab and golimumab improved joint symptoms in patients who failed previous treatments.
New research reveals how SIRT2 regulates T cell responses, potentially improving cancer immunotherapy and immune function.
A Phase 4 trial tests whether simplifying HIV treatment to two drugs worsens hidden viral replication and immune dysfunction.
A major review maps emerging immunotherapies—from JAK inhibitors to microbiome interventions—that could transform care for celiac and food allergy patients.
Review examines immunosuppressive drugs like cyclosporine and tacrolimus, highlighting new applications and safety management strategies.
Scientists develop potent α5β1 integrin inhibitor for inhalation therapy, offering new approach for severe asthma patients.
Researchers identify how TSLP protein creates regulatory T cells that suppress immune responses in melanoma.
JAK inhibitors outperform traditional treatments for rheumatoid arthritis but carry cardiovascular and infection risks.
Comprehensive review reveals autoimmune markers present before symptoms and highlights automated insulin delivery breakthroughs.
Pyruvate, a core metabolic molecule, suppresses interferon signaling by directly modifying STAT1 — linking metabolism to immune control.
A Phase 4 trial compares two antiretroviral strategies in treatment-naive HIV patients with dangerously low CD4 counts below 100.
